Aktienanalyse zu Transcode Therapeutics Inc (RNAZ)RNAZTranscode Therapeutics Inc

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Transcode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 25.149, indicating oversold conditions, and a staggering year-to-date change of -79.59%. The stock is currently trading at $1.51, significantly below its 52-week high of $12.60, which suggests a lack of investor confidence and potential for further declines. The main risk is its negative earnings trend, with a net income loss of -$19,510,296 in Q1 2026, which raises concerns about its financial viability.